Active Biotech: Notice of Annual General Meeting of Shareholders

(Thomson Reuters ONE) -


The Board of Directors of Active Biotech AB (publ) has issued a notice to the
Annual General Meeting, which is to take place at 5 p.m. on Thursday, May
10, 2012, at Edison Park, Emdalavägen 16 in Lund, Sweden.

Please see the attached notification, which is being announced within short in
Svenska Dagbladet and Post- och Inrikes Tidningar.



Lund, April 11, 2012

ACTIVE BIOTECH AB (PUBL)

THE BOARD OF DIRECTORS



About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC:ACTI) is a biotechnology company with focus
on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are
laquinimod, an orally administered small molecule with unique immunomodulatory
properties for the treatment of multiple sclerosis, TASQ for prostate cancer and
ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In
addition, laquinimod is in Phase II development for Crohn's and Lupus. Further
projects in clinical development comprise the two orally administered compounds,
57- 57 for Systemic Sclerosis as well as RhuDex(®) for RA. Please visit
www.activebiotech.com  for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00


Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication on April 11, 2012, at 8:30 a.m.



Notice of Annual General Meeting of Shareholders:
http://hugin.info/1002/R/1601111/505484.pdf



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and

other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE
[HUG#1601111]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 11.04.2012 - 08:30 Uhr
Sprache: Deutsch
News-ID 133714
Anzahl Zeichen: 2365

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 138 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech: Notice of Annual General Meeting of Shareholders"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech